(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of -33.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Sutro Biopharma's revenue in 2024 is $160,955,000.On average, 7 Wall Street analysts forecast STRO's revenue for 2024 to be $4,632,283,794, with the lowest STRO revenue forecast at $3,892,051,820, and the highest STRO revenue forecast at $5,543,700,082. On average, 6 Wall Street analysts forecast STRO's revenue for 2025 to be $5,061,398,999, with the lowest STRO revenue forecast at $2,550,448,364, and the highest STRO revenue forecast at $9,498,420,533.
In 2026, STRO is forecast to generate $3,589,593,217 in revenue, with the lowest revenue forecast at $876,536,247 and the highest revenue forecast at $5,417,538,233.